Efficacy of multi-layered human iPS cell-derived cardiovascular cell sheets in a pacing-induced canine dilated cardiomyopathy model

Yu Shimoyama and colleagues tested IHJ-301, a multilayered human induced-pluripotent-stem-cell-derived cardiovascular cell sheet, in a pacing-induced canine dilated cardiomyopathy model. The construct combined cardiomyocytes, endothelial cells, and stromal cells. Five dogs received epicardial implantation and six received sham surgery. Four weeks later, the change in left-ventricular ejection fraction was 9.38 ± 1.47 percentage points with IHJ-301 versus 1.90 ± 0.34 with sham (p<0.05). Fractional shortening, stroke volume, and cardiac output also favored the cell-sheet group. The model was designed to maintain depressed cardiac function without mortality, which makes treatment readout easier. This is a useful large-animal bridge study, but it is not a human trial and it says nothing about longevity. The sample is very small. Follow-up was four weeks after implantation. The paper does not establish long-term engraftment, arrhythmia risk, tumor risk, durability, or clinical benefit in people. The result supports continued translational testing of engineered cell sheets for heart failure. It does not justify clinic use or a generalized claim that iPSC therapies rejuvenate aging tissues.

We established a non-ischemic large-animal heart failure model that sustains depressed function for one month, enabling clear therapeutic readouts. IHJ-301 significantly improved multiple parameters of cardiac function, providing preclinical evidence that IHJ-301 could offer a promising therapeutic option for DCM.